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PolyMetformin combines carrier and anticancer
activities for in vivo siRNA delivery
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Metformin, a widely implemented anti-diabetic drug, exhibits potent anticancer efficacies.
Herein a polymeric construction of Metformin, PolyMetformin (PolyMet) is successfully
synthesized through conjugation of linear polyethylenimine (PEI) with dicyandiamide.
The delocalization of cationic charges in the biguanide groups of PolyMet reduces the toxicity
of PEI both in vitro and in vivo. Furthermore, the polycationic properties of PolyMet permits
capture of siRNA into a core-membrane structured lipid-polycation-hyaluronic acid (LPH)
nanoparticle for systemic gene delivery. Advances herein permit LPH-PolyMet nanoparticles
to facilitate VEGF siRNA delivery for VEGF knockdown in a human lung cancer xenograft,
leading to enhanced tumour suppressive efficacy. Even in the absence of RNAi, LPH-PolyMet
nanoparticles act similarly to Metformin and induce antitumour efficacy through activation of
the AMPK and inhibition of the mTOR. In essence, PolyMet successfully combines
the intrinsic anticancer efficacy of Metformin with the capacity to carry siRNA to enhance the
therapeutic activity of an anticancer gene therapy.
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T
he discovery of RNA interference (RNAi) has since
provided a conserved cellular pathway to modulate or
inhibit endogenous gene expression through short
interfering RNA (siRNA) therapeutics1,2. However, naked
siRNA is susceptible to degradation by nucleases in blood
serum and unable to cross the cell membrane due to its anionic
charge3,4. Thus, systemic delivery of RNAi therapeutics to
cancerous tissues remains a major challenge. To date, in vivo
siRNA delivery has been achieved by vector-based delivery
systems with cationic or ionizable characteristics, including
polycation5,6, lipid7–9 and inorganic nanoparticles10,11, and
RNA modifications/conjugations12,13. Among them, delivery
using cationic polymers composed of different cationic
compositions has become one of the most widely accepted
strategies for delivery of siRNA14,15. Yet, the functional
mechanisms of a polycation’s molecular composition on siRNA
delivery remain unclear16. Recently, materials have been
developed incorporating guanidine groups to increase cellular
uptake and transfection17,18. Herein a polycationic bi-guanidine
composed of the anticancer therapeutic, Metformin (dimethyl-bi-
guanide), has been developed for in vivo siRNA delivery.
Metformin, one of the most effective drugs against diabetes19,
is also known as a therapeutic agent against cancers including
lung cancer20,21, pancreatic cancer22, breast cancer23, gastric
cancer24,25 and so on. The anticancer efficacy of Metformin can
be primarily attributed to the activation of AMP-activated protein
kinase (AMPK)26,27 and inhibition of the mammalian target of
rapamycin (mTOR)28,29. This cationic small molecular drug
shows excellent tolerability and can be dosed at up to 2 g per day
due to low toxicity. Moreover, the cationic biguanide composition
of Metformin makes its polymeric form a desirable carrier
for siRNA delivery. Therefore, it is expected that polymeric
Metformin (PolyMet) would serves dual purposes as both a gene
carrier and an antitumour therapeutic to achieve combinational
therapeutic efficacies against cancer. Human non-small-cell lung
cancer (NSCLC) is a well-known, aggressive and metastatic
refractory tumour that responds to treatment by Metformin30,31.
Thus, a NSCLC tumour cell H460 was used to evaluate the
efficacy of siRNA delivery and antitumour abilities of PolyMet in
this study.
Our data show a possibility to facilitate vascular endothelial
growth factor (VEGF) siRNA in vivo delivery by PolyMet
nanoparticles and enhanced tumour growth. In the absence of
RNAi, LPH-PolyMet nanoparticles, like metformin, activated
the AMPK, inhibited the mTOR pathway and induced tumour
autophagy and apoptosis. Thus, PolyMet successfully combines
the intrinsic anticancer efficacy of Metformin with the capacity to
carry siRNA to enhance the therapeutic activity of an anticancer
gene therapy.
Results
Synthesis and characterization of PolyMet polymer. Inspired by
the fact that Metformin can be synthesized through a one-step
reaction of dimethylamine hydrochloride and 2-cyanoguanidine
(dicyandiamide), with heating (Supplementary Fig. 1), the
Metformin polymer was designed using a similar method.
To yield PolyMet, linear polyethylenimine (PEI) and dicyandia-
mide were reacted under heat in acidic conditions (Fig. 1a).
Linear PEI hydrochloride (0.2 g) and dicyandiamide (2 g) were
mixed in 10ml 2M HCl solution. The reaction mixture was
reacted at 100 C for 24 h, purified through an ultrafiltration tube
to remove excess dicyandiamide, washed with deionized water for
two times and lyophilized. The formation of PolyMet was verified
by using proton nuclear magnetic resonance (1H-NMR)
(Supplementary Fig. 2A) and matrix assisted laser desorption/
ionization time-of-flight (MALDI-TOF) (Supplementary
Fig. 2B,C) analyses. 1H-NMR (400MHz, d6-dimethylsulfoxide)
spectrum exhibits all characteristic proton resonance peaks cor-
responding to the present PolyMet molecules. The appearance of
the proton resonance at d 2.86–3.75 p.p.m. in the product along
with the characteristic guanidium proton at d 5.80–6.40 p.p.m.
confirmed the formation of biguanide polymer. The spectrum
also indicated near 95% substitution ratio of PolyMet by com-
paring the area ratios of PEI (2.53–2.70 p.p.m.) and PolyMet
(2.86–3.75 p.p.m.). MALDI-TOF of the PolyMet and free PEI
was performed to determine the synthesis of PolyMet
(Supplementary Fig. 2B,C). The distribution centre
for PEI (ca. 570Da) was completely red-shifted compared
with PolyMet (ca. 1600Da), which is consistent with the
1H-NMR result, indicating successful conjugation of PEI with
2-cyanoguanidine (Supplementary Fig. 2B). The average
molecular weight of PEI shown by MALDI-TOF analysis is
smaller than the molecular weight we used for synthesis
(ca. molecular weight is 4,300Da), which might be due to the
existence of numerous differently charged species of PEI,
since MALDI-TOF only detects singly charged species32.
Moreover, the extended MALDI-TOF mass spectra
(Supplementary Fig. 2C) show several series of oligomer ions
43 and 129m/z apart from each other, in agreement with the
PEI (43m/z for C2H5N unimer) and PolyMet (129m/z for
C4H11N5 unimer) repeat units, respectively. As described in
authoritative literatures33,34, Metformin can be characterized by
(1) using ultraviolet absorption at the wavelength of maximum
absorbance at about 233 nm or (2) exhibiting a red colour in
the solution of nitroprusside/potassium hexacyanoferrate(III)/
sodium hydroxide. Both PolyMet and Metformin exhibited a
maximum absorbance around 233 nm (Fig. 1b) and showed red
colour in the colour test in a dose-dependent manner (Fig. 1c).
These results suggest that after the reaction with dicyandiamide,
the secondary amines in PEI had been completely replaced with
biguanides.
Notably, PolyMet showed a significantly lower cytotoxicity
(Fig. 1d) and threefold higher maximum tolerable dose compared
with PEI (Supplementary Table 1), indicating PolyMet containing
guanidine is more tolerable than its secondary amine-containing
counterpart. But the lower maximum tolerable dose of PolyMet
than Metformin (Supplementary Table 1) is perhaps attributed to
the interaction of the cationic polymer with the serum proteins in
the blood. In summary, PolyMet as a cationic polymer may be
used to condense and deliver negatively charged siRNA with
similar pharmacological properties and activity to Metformin due
to the biguanide structure.
Preparation and characterization of LPH nanoparticles. It is
well documented that siRNA forms a loose and unstable complex
when mixed with only polycationic polymers due to its low
molecular weight and low charge density35,36. Therefore,
liposomes were used to coat complexes to protect siRNA from
dissociation or clearance before it reaches the tumour in our
study. First of all, hyaluronic acid (HA), a polyanionic and
multivalently charged polysaccharide, was used to facilitate
siRNA delivery and enhance the particle condensation. Then
cationic 1,2-dioleoyl-3-trimethylammonium-propane chloride
salt (DOTAP) liposome was applied to coat complex to prove
the stability of complex. These core/shell-type nanoparticles,
referred to the lipid-polycation-hyaluronic acid (LPH)
nanoparticle were established for systemic delivery of siRNAs to
the tumour site37,38. Specifically, HA was mixed
with siRNA at 1:1 mole ratio, and modulated the N/P ratios of
PolyMet/(HAþ siRNA) complex. Aggregates were observed at
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an N/P ratio around 0.9, where a neutral complex was formed.
In this case, 0.6 was chosen as the optimal ratio, as the complex
remained negatively charged (B  20mV) with a relatively small
size (B100 nm). At this ratio the PEI/(HAþ siRNA) complex
had a similar charge and size with PolyMet/(HAþ siRNA)
complex (Supplementary Fig. 3). Next, DOTAP/cholesterol
(1:1mol/mol) cationic liposomes were added to the complex to
form the lipid coating through charge–charge interactions.
Studies have shown that the NSCLC cell H460 overexpresses
sigma receptors17,39,40, thus a targeting ligand for the sigma
receptors, DSPE-PEG-anisamide, was used to deliver
nanoparticles to the tumour by the post-insertion method to
form the outer leaflet of the liposome membrane. The size,
distribution, morphology and the characteristics of the
nanoparticles are summarized in Fig. 2 and Supplementary
Table 2. The lipid coating reduced the complex’s size due to
electrostatic interactions. The final nanoparticles were 70–80 nm
with a positive charge of about 20mV and 4.38% loading
efficiency (Supplementary Table 2).
LPH-PolyMet combines siRNA carrier and anticancer activities.
Previous studies have shown that VEGF siRNA suppresses
angiogenesis and may be a potential therapeutic agent for
NSCLC41. Human NSCLC H460 tumour-bearing mice received
intravenous (i.v.) injections of different formulations with VEGF
siRNA or control siRNA every other day. On successive i.v.
injections into tumour-bearing mice, the greatest enhancement of
antitumour efficacy was observed when LPH-PolyMet-siVEGF
was administered (Fig. 3a).
Notably, the LPH-PolyMet-siCtrl group that contained control
siRNA also showed a partial tumour suppression activity,
indicating that poly-biguanide structure of PolyMet has the
antitumour activity. Meanwhile, minimal suppression of tumour
growth was found in the LPH-PEI-siCtrl group. One day after the
second injection, mice were killed and tumour lysates were
prepared for western blot. As shown in Fig. 3b, LPH-PolyMet-
siVEGF group showed robust knockdown of VEGF with about
95% of silencing compared with the phosphate-buffered saline
(PBS) group. LPH-PEI-siVEGF had only a partial effect on the
VEGF expression level with about 70% of knockdown in
comparison with control group. LPH-PolyMet-siCtrl showed a
slight knockdown effect. LPH-PEI-siCtrl had no measurable
effect on the protein expression level of VEGF.
Terminal deoxynucleotidyl transferase dUTP nick end labelling
(TUNEL) assay further confirmed the induction of apoptotic cells
in tumours (Fig. 3c). The number of TUNEL-positive apoptotic
cells after LPH-PolyMet-siVEGF treatment was about 40%, which
was the highest among all groups. This indicates that elevated
apoptosis occurred after downregulation of VEGF expression,
which is consistent with studies reported elsewhere42. Treatment
with LPH-PEI-siVEGF could only induced apoptosis in
about 20% of cells. Importantly, we also observed that LPH-
PolyMet-siCtrl exhibited significant higher TUNEL-positive
population compared with PBS or LPH-PEI-siCtrl, indicating
the apoptotic capability of PolyMet gene carrier itself.
PolyMet LPH was then investigated to determine its ability to
carry other therapeutic siRNA. As an anti-apoptotic protein
BCL-2 promotes cell survival, and inhibition of BCL-2 can
suppress tumour growth43,44. Herein siRNA used against BCL2
inhibited tumour growth, especially in the LPH-PolyMet-siBCL2
treatment group, which provided persistent suppression of
tumour growth (Supplementary Fig. 4A). The level of BCL-2
after treatment was detected by western blot analysis, LPH-
PolyMet-siBCL2 induced a significant downregulation of BCL-2
level in comparison with all other groups (Supplementary Fig. 4B)
and the TUNEL assay further confirmed the induction of
apoptotic cells in tumours. The number of TUNEL-positive
apoptotic cells after LPH-PolyMet-siBCL2 treatment was about
70%, which was significantly higher than all other groups
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Figure 1 | Synthesis and characterization of PolyMet. (a) Synthesis scheme of PolyMet polymer. (b) Ultraviolet spectra of Metformin, PEI and PolyMet in
the range of 220–300nm. (c) Colour test of Metformin, PEI and PolyMet. Test reagents were prepared by mixing equal volumes of 10% w/v sodium
nitroprusside with 10% w/v potassium hexacyanoferrate (III) and 10% sodium hydroxide. Equal amounts of Metformin, PEI unimer or PolyMet unimer in
aqueous solution were mixed with 100ml of the test reagent. The image was taken 30min after mixing. (d) Cytotoxicity of Metformin, PEI and PolyMet.
H460 cell availability was measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay after 24h of exposure to Metformin,
PolyMet and PEI solutions. Data are mean±s.d. (n¼ 8). Data are representative of b and c or combined (d) from three independent experiments.
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(Supplementary Fig. 4C). This indicates that elevated apoptosis
occurred after downregulation of BCL2 anti-apoptotic protein
expression in the LPH-PolyMet-siBCL2 group.
PolyMet was then tested for gene delivery and tumour
inhibition in a melanoma model. As shown in Supplementary
Fig. 5, the most effective treatment, LPH-PolyMet-siVEGF
resulted in a knockdown of VEGF level by B70% and a
suppression of tumour growth by about 80% in comparison with
the PBS group in a 1205Lu melanoma model. Meanwhile,
LPH-PEI-siVEGF also suppressed tumour growth effectively, but
not as persistently as LPH-PolyMet-siVEGF.
Moreover, the antitumour activity of PolyMet was compared
with other two commonly used polycations, poly-L-lysine (PLL)
and protamine. PLL and Protamine were formulated in the LPH
systems containing the same amount of VEGF siRNA as PolyMet.
The antitumour efficacy and VEGF knockdown were presented in
Supplementary Fig. 6. All LPH formulations had significantly
suppressed tumour growth in comparison with PBS. However,
there was no significant difference among PEI, PLL and
protamine. The greatest enhancement of antitumour effect was
observed with PolyMet. The expression of VEGF was also
evaluated after day 16, as shown in Supplementary Fig. 6B. The
VEGF level in the tumour was significantly lower than other
groups, as well as the PBS control. Thus, PolyMet showed the
greatest antitumour activity among all four polycations tested.
Mechanisms of PolyMet on the inhibition of tumour growth.
Both clinical and preclinical studies have shown that Metformin
improved survival and/or antitumour efficacy25,45. Results
shown in Fig. 3 and Supplementary Figs 4, 5 and 6B indicate
the tumour growth inhibition of LPH-PolyMet-siCtrl. It was
thus hypothesized that in the absence of RNAi, PolyMet, like
its unimer Metformin, may be responsible for some part of
anticancer activity. The effect of LPH-PolyMet and different
nanoparticles on an H460 xenograft was studied. As shown in
Fig. 4, treatment with LPH-PolyMet led to significant inhibition
of cancer growth in comparison with PBS. A noticeable difference
in tumour growth inhibition was observed between LPH-PEI and
LPH-PolyMet (Fig. 4a), suggesting that PolyMet played an
important role in enhancing antitumour activity. At the end of
the experiment, the tumours of the animals treated with
LPH-PolyMet were o1% of the total body weight, which was
significantly smaller than the LPH-PEI (4%) and PBS (6%)
groups (Fig. 4b). Moreover, no toxicity was detected in blood
haematology serum chemistry or the histology of the major
tissues (Supplementary Fig. 7 and Supplementary Table 3).
Furthermore, we compared the effect of LPH-PolyMet siRNA
nanoparticles with Metformin in an H460 xenograft
(Supplementary Fig. 8). Free Metformin (1.25mg kg 1)
equivalent to the unimer dose of PolyMet (1.25mg kg 1) that
was required to deliver 0.625mg kg 1 of VEGF siRNA was used
in the study. It was confirmed that there is no significant
difference between the PolyMet carrier (LPH-PolyMet-siCtrl) and
Metformin, indicating that biguanide in the PolyMet copolymers
are associated with the anticancer activities of Metformin. Both of
the groups exhibit significantly higher antitumour growth activity
compared with LPH-PEI-siCtrl or PBS while LPH-PolyMet-
siVEGF has the best antitumour efficacy. In this case tumour
growth was suppressed seven- to eightfold compared with the
PBS group, and about twofold compared with the PolyMet carrier
or the Metformin group, which suggests again that PolyMet
successfully combine the intrinsic anticancer efficacy of
Metformin with the tumour suppressive effects of VEGF siRNA
to enhance the therapeutic activity of an anticancer gene therapy.
It has been reported that Metformin inhibits cancer cells by
activating the AMPK and inhibiting the mTOR pathways28,46.
We checked the activity of PolyMet in these pathways and
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Figure 2 | Schematic illustration and representative TEM images of PolyMet nanoparticles. Anionic HAþ siRNA mixture was condensed by cationic
PolyMet into a negatively charged PolyMet/(HAþ siRNA) complex (a,c). DOTAP/cholesterol cationic liposomes were added to the complex to form lipid
coating, then DSPE-PEG and DSPE-PEG-anisamide were used to liposome by the post-insertion method to form LPH-PolyMet final nanoparticles (b,d).
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compared it with that of Metformin. AMPK acts as a metabolic
tumour suppressor that governs glucose and lipid metabolism47.
In many cases, a low level of phosphorylation of AMPK is
correlated with poor prognosis after cancer treatment48.
We observed that following treatment with Metformin or
LPH-PolyMet, phosphorylation levels of AMPKa in the H460
tumour were significantly enhanced compared with the PBS
group (Fig. 5a). The activation of AMPKa did not occur in
the LPH-PEI group, suggesting PolyMet is the key factor in the
nanoparticle that can activate AMPKa pathway. mTOR is a
downstream effector of AMPK49. AMPK activation inhibits
mTOR and its downstream effector kinases50. Phosphorylation of
mTOR plays a pivotal role in the proliferation and survival of
cancer cells51. Therefore, we then evaluated the effects of
treatments on the activity of mTOR (Fig. 5a). Metformin and
LPH-PolyMet treatments led to a significant inhibition of mTOR
activity indicated by stronger reduction in p-mTOR/mTOR levels
compared with the PBS group. The activity was not shared by
LPH-PEI.
Autophagy is recognized as a potentially toxic mechanism for
Metformin that results in the inhibition of cancer growth52,53. We
evaluated whether autophagy can also be observed after treatment
of LPH-PolyMet. Microtubule-associated protein light chain 3 b
(LC3b) is a specific marker for autophagy initiation54. As shown
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Figure 3 | LPH nanoparticles composed of PolyMet can systemically deliver VEGF siRNA to the tumour site and inhibit tumour growth. (a) H460
tumour-bearing mice were injected i.v. every other day and tumour volumes were measured every day. (b) H460 tumour VEGF protein levels after two
injections were measured by western blot analysis. Bar chart in b represent quantitative analysis of relative normalized VEGF band intensity (Image J).
(c) TUNEL staining (green) in H460 tumour cells after treatment with siRNA in different formulations in vivo. Nucleic acid was stained with 4,6-diamidino-
2-phenylindole (blue). Bar chart in c is a quantitative analysis of % of TUNEL-positive cells. Five randomly selected microscopic fields were quantitatively
analysed on Image J. Data are mean±s.e.m. (n¼ 5 per group) analysed by two-way analysis of variance with Tukey’s correction. Data are representative of
b and c or combined from (a) three independent experiments. NS, not significant; *Po0.05, **Po0.01, ***Po0.005. Scale bar, 200mm.
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in Fig. 5b, Metformin- and LPH-PolyMet-treated tumours
showed a higher LC3b-associated red fluorescence than other
groups, indicating that both Metformin and LPH-PolyMet could
induce autophagy in the H460 lung cancer xenograft model.
Finally, the mechanism of the antitumour efficacy after
treatment was determined by the TUNEL assay, a common
method to test for apoptosis (Fig. 5b). The per cent of apoptotic
cells after Metformin or LPH-PolyMet treatments was 12.4% and
15%, respectively, while no significant apoptosis induction was
observed in other groups. This suggests that Metformin or
polymer form can induce cell apoptosis and play a critical role in
regulating the cancer cell survival.
Discussion
Nanotechnology has been extensively exploited to prolong the
circulation time and to enhance the therapeutic activity for a
variety of drugs. After systemic injection the nanoparticles drain
through the leaky tumour blood vessels and are retained at
the tumour site, resulting in increased tumour accumulation of
the nanoparticle-formulated drug compared with the free drug.
This well-documented phenomenon is referred to as the
enhanced permeability and retention effect55. Thus,
nanoparticles offer a number of advantages over free drugs,
which make them an ideal delivery vehicle for Metformin.
However, due to its high hydrophilicity, Metformin cannot be
effectively loaded into established nanocarriers, which explains
why only few Metformin nanoparticles have been reported56–58.
Recently, Yang et al.56 reported the co-encapsulation of
epirubicin and Metformin into liposomes through remote
loading. This nanoparticle successfully inhibited the growth of
CD133þ cancer stem-like cells. Jose et al.57 developed
Metformin-loaded bovine serum albumin nanoparticles
(MET-BSA) by the coacervation method and observed that
MET-BSA nanoparticle showed higher efficacy than Metformin
alone or the BSA carrier itself. However, PolyMet, which
combines both gene delivery and anticancer capabilities,
represents a novel approach.
Guanidination of a polymer enhances the activity for gene
delivery and has considerably less toxicity compared with primary
amines of the polymer59,60. The guanidine has been found to
readily pass through the non-polar membrane of a cell and even
across tissue barriers by possibly forming a bidentate hydrogen
bond with anionic cell surface phosphate, carboxylates and/or
sulfates on the cell surface61,62. Materials have been previously
developed incorporating guanidine groups to increase cellular
uptake and transfection60,63–65. For example, Lee et al.60 used
pyrazole-1-carboxamidine to react with branched PEI, and
observed enhancement of transfection efficiency and decreased
cytotoxicity of PEI by guanidylation. Wender et al. developed
non-natural guanidinium-rich molecular transporters to enhance
cellular uptake61,66, through tunable polyguanidino dendrimers,
and observed higher cellular uptake65. Guanidinium-rich
molecular transporters can penetrate cells and overcome
efflux-mediated multidrug resistance67. Although these
previously reported polyguanidines are established gene carriers,
the carriers themselves fail to exhibit anticancer activity without
their therapeutic agent. Thus, PolyMet serves as both a gene
carrier and anticancer therapeutic. However, findings presented
herein have not been investigated with PolyMet against a
p53-deficient tumour, which remains to be further explored.
The focus of this study is to show the carrier and anticancer
activities of PolyMet. The dose of PolyMet used in the study was
dictated by the dose of siRNA and was only a fraction of the
effective dose of metformin. Further study with increased
PolyMet dose will bring the new polymer a step closer to the
clinical translation.
Methods
Materials. DOTAP and 1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethyleneglycol-2000) ammonium salt (DSPE-PEG2000) were
purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). DSPE-PEG-anisamide
was synthesized in our lab as described previously68. DeadEnd Fluorometric
TUNEL assay kits and Luciferase Assay System assay substrates were obtained
from Promega (Madison, WI). Linear PEI hydrochloride with average molecular
weight 8,000, dicyandiamide, HA and other chemicals were obtained from Sigma-
Aldrich (St. Louis, MO). Rabbit monoclonal antibodies Phospho-AMPKa(Thr172)
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Figure 4 | Metformin and PolyMet inhibit H460 tumour growth. PBS, Metformin, LPH-PEI and LPH-PolyMet were administered i.v. every other day, and
mice were killed 24 h after the final injection. (a) Tumour volumes were measured every day. (b) Tumour weights were measured on day after final injection
and compared with body weights to determine the percentage of tumour burden. (c) Visual observations of the H460 tumour sizes in each treatment
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from a and b or representative of (c) three independent experiments. NS, not significant; *Po0.05, **Po0.01, ***Po0.005.
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(40H9) (catalogue # 2535), AMPKa (D5A2) (catalogue # 5831), Phospho-mTOR
(Ser2448) (D9C2) XP (catalogue # 5536), mTOR (7C10) (catalogue # 2983), LC3b
(D11) XP (catalogue # 3868), GAPDH (14C10) (catalogue # 2118) and Anti-rabbit
IgG, horseradish peroxidase-linked Antibody (catalogue # 7074) were purchased
from Cell Signaling Technology (Beverly, MA). BCL2 siRNA (target sequence:
50-AACAUCGCCCUGUGGAUGACU-30), VEGF siRNA (target sequence:
50-ACCUCACCAAGGCCAGCAC-30) and control siRNA (target sequence:
50-AAUUCUCCGAACGUGUCACGU-30) were synthesized by Sigma-Aldrich.
Cell culture. H460 human NSCLC cells and 1205Lu melanoma cancer cells were
originally obtained from American Type Culture Collection and were cultured in
DMEM medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine
serum (Life Technologies, Carlsbad, CA), 100Uml 1 penicillin and 100mgml 1
streptomycin (Invitrogen). Cells were cultured in a humidified incubator at 37 C
and 5% CO2.
Experimental animals. Female nude female mice and female CD1 mice that were 6–
8 weeks old were used in the studies. Female nude mice were purchased from National
Cancer Institute (Bethesda, MD) and bred by the Division of Laboratory Animal
Medicine at University of North Carolina at Chapel Hill. CD1 mice were purchased
from Charles River Laboratories (Morrisville, NC). To establish the xenograft models,
5 106 cells in 100ml of PBS were injected subcutaneously into the right flank of the
mice. All work performed on animals was approved by the Institutional Animal Care
and Use Committee at the University of North Carolina at Chapel Hill.
Preparation of PolyMet. To prepare PolyMet, 0.2 g of linear PEI and 2 g of
dicyandiamide were mixed in 10ml 2M HCl solution. The compounds reacted at
100 C in the oil bath for 24 h. PolyMet was then purified through an ultrafiltration
tube, washed with deionized (DI) water for two times and lyophilized. The working
solution of PolyMet was diluted in DI water and kept as 1mgml 1, 1ml aliquots
for experiment. To verify the formation of PolyMet, NMR and MALDI-TOF
analyses were performed (Supplementary Methods).
Optimization of the PolyMet-HA or PEI-HA complexes. A volume of 200 ml of
PEI solution (containing 5, 10, 15 or 20 mg PEI in DI water) or 200ml of PolyMet
solution (containing 50, 60, 70 or 80 mg PolyMet in DI water) was mixed with
200 ml of HA (containing 50mg HA, in DI water) in a 1.5-ml tube. The complexes
were mixed by pipetting up and down for 10 times and allowed to stand at room
temperature for 10min. The optimal ratio of the complex was determined by the
results from particle size and zeta potential determined by dynamic light scattering
using a Malvern ZetaSizer Nano series (Westborough, MA).
Preparation of LPH nanoparticles. DOTAP/cholesterol liposomes were prepared
as follows: DOTAP (20mM, 1ml) and cholesterol (20mM, 1ml) were dissolved
(1:1mol/mol) in chloroform and the solvent was removed under reduced pressure.
The lipid film was then hydrated overnight with 2ml distilled water to form
cationic liposomes (10mM), which were sequentially extruded through poly-
carbonate membranes (200 nm 20 times, 100 nm 20 times and 50 nm 20
times) (Millipore, Billerica, MA). LPH cores were prepared by mixing 100 ml of 5%
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Figure 5 | Metformin and PolyMet inhibit tumour growth by activating the AMPK and inhibiting the mTOR pathways, inducing autophagy and
apoptosis mechanisms. Mice bearing H460 tumours were given i.v. injections every other day and tumour proteins was prepared 24 h after the second
injection for analysis. Bar charts in (a) represent quantitative analysis of normalized p-AMPK and p-mTOR band intensity using Image J. Data are shown as
mean±s.d. (n¼ 3). Cells under autophagy were stained by LC3b antibody (red) and apoptosis of cells was indicated by TUNEL assay (green). Nuclei were
stained blue. Bar charts in (b) are quantitative analysis of percentage of LC3b-positive cells and the percentage of TUNEL-positive cells, respectively. Five
randomly selected microscopic fields were analysed using Image J. Data are analyzed by two-way analysis of variance (ANOVA) with Tukey’s correction.
Data are shown as mean±s.d. (n¼ 5) and represent three independent experiments; NS, not significant; *Po0.05, **Po0.01, ***Po0.005. Scale bar,
200mm.
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glucose solution A (containing the 12.5 mg of siRNA and 12.5 mg of HA) with 100 ml
of 5% glucose solution B (containing 5 mg of PEI, or 25mg of PolyMet, or 6 mg of
PLL, or 13mg of Protamine) and incubated at room temperature for 10min. The
LPH cores were then mixed with 30 ml of cationic DOTAP/cholesterol liposomes
and incubated at room temperature for 10min to ensure proper lipid coating. The
lipid-coated nanoparticles were PEGylated using a post-insertional approach by
adding 10 ml DSPE-PEG (10mgml 1) and 10ml DSPE-PEG-anisamide
(10mgml 1) and incubating the nanoparticles at 50 C for 15min.
Characterization of LPH NPs. The size and surface charge of LPH cores and final
particles were determined by using a Malvern ZS90 Zetasizer (Worcestershire,
UK). Transmission electron microscope images of LPH were acquired through the
use of JEOL 100CX II transmission electron microscope (Tokyo, Japan). Briefly,
freshly prepared LPH nanoparticles (5ml) were carefully dropped onto a 300-mesh
carbon-coated copper grid (Ted Pella, Inc., Redding, CA) and allowed to stand at
room temperature for 5min. Grids were then stained with 1% uranyl acetate (5 ml)
and allowed to incubate briefly (10 s) and quickly dry. All images were acquired at
an accelerating voltage of 100 kV.
Loading capacity of LPH nanoparticles. After final LPH-PolyMet-siRNA
formulation, the free siRNA were separated by centrifugation for 20min at 18,000g
and 4 C. The siRNA concentration in the supernatant was measured by the
Quant-iT RiboGreen RNA reagent according to the manufacturer’s instructions,
using a fluorescence spectrometer (Perkin-Elmer, Waltham, MA) at 485/520 nm
excitation/emission. Each sample was assayed in triplicate.
siRNA loading ¼ Actual siRNA loading ðmgÞ
Weight of nanoparticles ðmgÞ100 %
Animal tumour model and antitumour activity. H460 human lung cancer cells
(5.0 106) were subcutaneously injected into the right flanks of female athymic nu/
nu mice. Drugs were administrated i.v. into mice when the tumours reached about
50–80mm3 in size (5–7 days after transplantation). LPH equivalent to
0.625mgkg 1 of VEGF siRNA or control siRNA, prepared as described above, were
i.v. injected every other day. Free Metformin (1.25mgkg 1) equivalent to the
unimer dose of PolyMet (1.25mgkg 1) that was required to deliver 0.625mgkg 1
of siRNA was used in the study. Animal weight and tumour volumes were measured
every other day. The tumour length (L) and width (W) were used to calculate volume
(V) by the following equation: V¼ 1/2 LW2. Serum biochemical value analysis
and haematology assay were provided in Supplementary Methods.
Western blot analysis. Western blotting was used to evaluate the protein
expression of tumour cells after systemic administration. Tumour-bearing mice
were injected i.v. every other day and were killed 24 h after the second injection.
A unit of 50mg of tumour was collected randomly via biopsy and homogenized
with a Tissue Master-125 homogenizer (OMNI International) in 500 ml cold
radioimmunoprecipitation assay buffer (Sigma-Aldrich) supplemented with 1%
protease inhibitor cocktail (Sigma-Aldrich) for 30min. Total homogenate was then
spun down at 13,000g with a tabletop centrifuge for 10min at 4 C. Supernatant
was collected and protein sample was quantified using a bicinchoninic acid assay
kit in accordance with the manufacturer’s instruction (Pierce Biotech). Samples
were diluted in 4 sample buffer and 10 sample-reducing reagent (Thermo
Fisher). A unit of 40mg protein from each group was separated by 4–12%
SDS–PAGE electrophoresis (Invitrogen) and transferred to a polyvinylidene
difluoride membrane (Bio-Rad). Membranes were blocked with 5% non-fat dry
milk (Bio-Rad) for 1 h at room temperature and then incubated with primary
antibodies (1:1,000 dilution; Cell Signal) overnight at 4 C. The membranes were
washed three times with PBS-Tween, followed by incubation with horseradish
peroxidase-conjugated secondary antibody (1:4,000 dilution; Cell Signal) for 1 h at
room temperature. Finally, the membranes were washed three times with
PBS-Tween and developed using Pierce ECL Western Blotting substrate (Thermo
Scientific). The expression level of targeted protein was quantified by ImageJ
software (NIH). GAPDH was detected as loading control. Images have been
cropped for presentation but are otherwise unmodified. Full-size images are
presented in Supplementary Figs 9 and 10.
Immunostaining. The TUNEL assay was used to detect apoptotic tumour cells
after systemic administration. Briefly, tumours were collected and fixed in freshly
prepared 4% paraformaldehyde or 10% formalin for 1 day. Tumour samples were
paraffin-embedded and sectioned by the UNC Animal Histopathology Core. The
slides were then deparaffinized in xylene and rehydrated through a gradient alcohol
series. The TUNEL staining was performed in accordance with the manufacturer’s
protocol (Promega). Nuclei of tumour cells were stained with DAPI (Vector
Laboratories). Images of were taken using a fluorescence microscope (Nikon).
The percentage of apoptotic cells was calculated by dividing the number of
apoptotic cells from the total number of cells in each microscopic field.
Representative microscopic fields (n¼ 5) were randomly selected in each treatment
group for this analysis.
Statistics analysis. All statistical analyses were carried out using GraphPad Prism
Software (Version 5.0, GrapPad Software, San Diego, CA).
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